Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H12N5O5P |
Molecular Weight | 289.1851 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC2=C(N=CN2CCOCP(O)(O)=O)C(=O)N1
InChI
InChIKey=NZVORGQIEFTOQZ-UHFFFAOYSA-N
InChI=1S/C8H12N5O5P/c9-8-11-6-5(7(14)12-8)10-3-13(6)1-2-18-4-19(15,16)17/h3H,1-2,4H2,(H2,15,16,17)(H3,9,11,12,14)
Molecular Formula | C8H12N5O5P |
Molecular Weight | 289.1851 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Rabacfosadine was approved in 2017 under the brand name Tanovea-CA1 for the treatment of canine lymphoma. In addition, this drug has demonstrated effectiveness against non-Hodgkin's lymphoma in dogs, as well as canine cutaneous T-cell lymphoma, and relapsed canine B-cell lymphoma. Rabacfosadine a prodrug, which is hydrolyzed intracellularly to the metabolites, 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP) and 9-(2-phosphonylmethoxyethyl) guanine (PMEG). PMEG is then converted to its active phosphorylated form, which is a chain-terminating inhibitor of the replicative deoxyribonucleic acid (DNA) polymerases.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL613496 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8669893 |
1.7 µM [EC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=407d42d7-2e23-4e90-aff0-b8b05d226e4b
Curator's Comment: in dogs
Administer TANOVEA-CA1 at 1 mg/kg body weight as a 30-minute intravenous infusion, once every three weeks, for up to five doses. Stepwise dose reductions to 0.8 mg/kg and 0.66 mg/kg or dose delays may be used to manage adverse reactions.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:35:45 GMT 2023
by
admin
on
Sat Dec 16 08:35:45 GMT 2023
|
Record UNII |
N9YOI96LPP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
114088-58-3
Created by
admin on Sat Dec 16 08:35:45 GMT 2023 , Edited by admin on Sat Dec 16 08:35:45 GMT 2023
|
PRIMARY | |||
|
PMEG (antiviral)
Created by
admin on Sat Dec 16 08:35:45 GMT 2023 , Edited by admin on Sat Dec 16 08:35:45 GMT 2023
|
PRIMARY | |||
|
N9YOI96LPP
Created by
admin on Sat Dec 16 08:35:45 GMT 2023 , Edited by admin on Sat Dec 16 08:35:45 GMT 2023
|
PRIMARY | |||
|
135409438
Created by
admin on Sat Dec 16 08:35:45 GMT 2023 , Edited by admin on Sat Dec 16 08:35:45 GMT 2023
|
PRIMARY | |||
|
DTXSID90150649
Created by
admin on Sat Dec 16 08:35:45 GMT 2023 , Edited by admin on Sat Dec 16 08:35:45 GMT 2023
|
PRIMARY | |||
|
m12245
Created by
admin on Sat Dec 16 08:35:45 GMT 2023 , Edited by admin on Sat Dec 16 08:35:45 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE | |||
|
PRODRUG -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |